Browse News
Filter News
Found 86 articles
-
Cancer Gene Therapy Industry is Rising Rapidly Up to USD 18.11 Bn by 2033
4/18/2024
The global cancer gene therapy market size was accounted for USD 2.95 billion in 2023 and it is increasing around USD 18.11 billion by 2033
-
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates
3/27/2024
Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.
-
Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published
2/15/2024
Vaxxinity, Inc., a U.S. company pioneering the development of a new class of medicines, announced the publication of data from multiple non-human primate studies demonstrating that VXX-401 reproducibly lowers low-density lipoprotein cholesterol in non-human primates.
-
Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida
1/30/2024
Vaxxinity, Inc. today announced a research collaboration with the University of Florida’s (UF) Center for Translational Research in Neurodegenerative Disease (CTRND) to support its work on the development of vaccines for neurodegenerative diseases.
-
Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference
1/3/2024
Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today announced that Mei Mei Hu, Chief Executive Officer of Vaxxinity, will present an update on the Company and its pipeline at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024, at 10:30am PST.
-
AstraZeneca advances scientific leadership in hematology at ASH 2023
11/29/2023
AstraZeneca will present new clinical and real-world data in multiple hematological conditions at the 65th American Society of Hematology (ASH) Annual Meeting andExposition, December 9 to 12, 2023 in San Diego, CA.
-
Rosalind Franklin University Announces New Director of Center for Genetic Diseases
11/16/2023
Rosalind Franklin University of Medicine and Science announces the appointment of molecular biologist Weihang “Valerie” Chai, PhD, as director of the Center for Genetic Diseases.
-
Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update
11/8/2023
Vaxxinity, Inc. today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.
-
Anbio Biotechnology made a successful first presence at AACC Middle East 2023
10/12/2023
Anbio Biotechnology (“Anbio”), a leading provider of innovative diagnostic solutions, successfully showcased its debut at AACC Middle East 2023 held in Dubai from October 7-8, 2023.
-
Vaxxinity to Present at Upcoming Investor Conferences in September 2023
8/29/2023
Vaxxinity, Inc., a U.S. company pioneering the development of a new class of medicines, announced that Mei Mei Hu, Chief Executive Officer of Vaxxinity, will present and participate in meetings at the following investor conferences in New York in September.
-
Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Disease
8/10/2023
Vaxxinity, Inc. announced the print publication of Phase 2a clinical trial data in The Lancet’s eBioMedicine, stating that UB-311 “was safe and well-tolerated,” with early clinical data demonstrating a trend for slowing cognitive decline in mild Alzheimer’s disease.
-
Vaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate Update
8/9/2023
Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.
-
Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director
7/27/2023
Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, announced that Peter Powchik, M.D., will join Vaxxinity’s leadership team as Executive Vice President, Global Scientific Director starting October 1, 2023.
-
Vaxxinity Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson’s Patients
7/17/2023
Vaxxinity, Inc. today announced new data from a Phase 1 clinical trial demonstrating that antibodies derived from its investigational immunotherapeutic for Parkinson’s disease (PD), UB-312, slows seeding of alpha-synuclein (aSyn) in cerebrospinal fluid (CSF) of patients with PD as demonstrated using multiple target engagement assays.
-
Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson’s Disease
6/22/2023
Vaxxinity, Inc. today announced positive results from Part B of its Phase 1 clinical trial of UB-312, an investigational vaccine for Parkinson’s disease (PD), demonstrating UB-312 was well-tolerated and induced anti-alpha-synuclein (aSyn) antibody responses in participants with early PD, meeting the primary objectives of the trial.
-
SUSTAINEXT PROJECT: SHOWCASING A NEXT-GENERATION, ZERO-WASTE, DYNAMIC MODEL OF BIOREFINERY FROM EXTREMADURA TO THE BIO-BASED INDUSTRY IN THE EU
6/21/2023
The first European-funded CBE flagship for botanical extract manufacturing
-
Vaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate Update
5/9/2023
Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.
-
Vaxxinity to Present at World Vaccine Congress, American Academy of Neurology, and BNA2023 Festival of Neuroscience in April
3/28/2023
Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that members of its leadership team will present data on investigational vaccines for COVID-19 and neurodegenerative diseases at three upcoming scientific and medical conferences in April.
-
Vaxxinity Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Updates
3/27/2023
Vaxxinity, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2022.
-
Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat Hypercholesterolemia
3/20/2023
Vaxxinity, Inc. today announced that the first subjects have been dosed in a randomized, double-blind, placebo-controlled Phase 1 clinical trial of VXX-401.